Montvida O, et al. - The purpose herein was to inform patients with type 2 diabetes and their carers about the probability of reducing HbA1c to clinically desirable levels and sustainability of such control over 2 years with major second-line anti-diabetic therapies under individual risk scenario, with and without third-line intensification. A prominently higher probability of achieving and sustaining glycaemic control over two years without further intensification was gained via second-line incretins and thiazolidinedione compared to sulfonylurea or insulin treatment.